Jay Hancock
Jay Hancock joined Kaiser Health News in 2012 from The Baltimore Sun, where he wrote a column on business and finance. Previously he covered the State Department and the economics beat for The Sun and healthcare for The Virginian-Pilot of Norfolk and the Daily Press of Newport News.
-
This is why Novartis paid Trump’s lawyer Michael Cohen $1.2 million
Hiring the president’s personal attorney matches a history of aggressively courting government officials by a corporation with much to lose in the debate over high drug prices.
-
Could failing proton centers be a sign of a healthcare bubble?
Health systems rushed enthusiastically into expensive medical technologies such as proton beam centers. But now that employers, insurers and government seem determined to curb growth in healthcare spending and to combat overcharges and wasteful procedures, such bets are less of a sure thing.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
A look at how one pharma company responded to the pressure on drug prices: Ramping up political activity
The pharma industry as a whole has cranked up political contributions and lobbying. Meanwhile, despite much talk about change, Congress and the Trump administration have done little to control drug prices or threaten drug-company profits.
-
Battleground on drug price legislation shifts to states and so does lobbying by PhRMA
With federal officials seemingly unwilling or unable to come up with legislation to control skyrocketing drug prices, that task is increasingly moving to the states. But so is pharma muscle and money opposing the measures.
-
Facing showdown on high drug prices, industry group PhRMA revenue surges to highest level in 7 years
Pharmaceutical Research and Manufacturers of America’s state and federal lobbying spending rose by more than two-thirds from the previous year, to $57 million.
-
Turmoil with ACA individual insurance marketplace abounds under Trump administration
Many of plans that people relied on for 2017 are being canceled, the result of insurers exiting the marketplaces or redesigning coverage to try to keep premiums down.
-
Outcome far from certain in legal battle over cost-sharing ACA payments
A legal fight over the federal government’s practice of paying cost-sharing reduction subsidies to insurers as part of the Affordable Care Act inched ahead with a small victory for insurers this week.
-
Back where we started? Senate health bill adds uncertainty for people with chronic conditions
Insurers were struggling last week to grasp the implications of the legislation, studded with ambiguous language. One big takeaway: The Senate’s version of health care would undermine historical assumptions and drastically shift risk in the individual market.
-
Loopholes in Senate healthcare bill risk eroding coverage for pre-existing conditions
Built into the bill are loopholes for states to bypass those protections and erode coverage for preexisting conditions.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
As House health bill vote nears, what would be consequences of dumping essential benefits?
Experts on both sides of the debate say it will likely also induce insurers to offer much skimpier plans, potentially excluding the gravely ill.
-
Australian biotech company offered sweetheart investment deal to Tom Price
Price told HHS ethics officials Thursday that if appointed to be HHS secretary, he will divest himself of the Australian stock as well as stock in about 40 other companies that could pose conflicts.
-
Insurance companies need to fix their provider directories
Flawed directories are “a real barrier to accessing the care and accessing the insurance consumers have purchased.”
-
ACA replacement may not be all that radical
Topping the list of ACA provisions likely to survive under Trump is the requirement that employers cover workers’ children up to the age of 26, analysts said.
-
Researchers visualize dubious benefits of many ‘routine’ screening tests
Under the growing philosophy of “shared decision-making,” they just want patients to have a good conversation about what procedures can and can’t do. Then patients decide.
-
Baltimore’s population health ‘moonshot’ aims at racial disparities
Baltimore officials presented a 10-year plan Tuesday that sharply highlights the poor health status of African-Americans and aims to bring black rates of lead poisoning, heart disease, obesity, smoking and overdoses more in line with those of whites.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
